Report : Europe Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type (Laser Therapy, Compression Devices and Bandaging, Drug Therapy, Physiological Procedures {Lymphovenous Anastomosis (LVA) and Vascularized Lymph Node Transfer (VLNT)}, Debulking Procedures {Surgical Debulking, Liposuction, and Others}, and Others), and End User (Hospitals, Clinics, Clinical Research Organizations, and Others)Â
Secondary Lymphedema Segment to Dominate Europe Lymphedema Treatment Market during 2021–2028
According to a new market research study on “Europe Lymphedema Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Condition Type, Treatment Type and End-User” is expected to reach US$ 3,953.12 million by 2028 from US$ 2,801.39 million in 2021. The market is estimated to grow at a CAGR of 5.0% from 2021 to 2028. The report provides trends prevailing in the Europe lymphedema treatment market along with the drivers and restraints pertaining to the market growth. Increasing healthcare facilities is the major factor driving the growth of the Europe lymphedema treatment market. However, issues associated with the lack of awareness and skilled professionals hinder the growth of Europe lymphedema treatment market.
The Europe lymphedema treatment market is segmented into condition type, treatment type, end-user and country. Based on type, the Europe lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market in 2020 and primary lymphedema is expected to be the fastest growing during the forecast period. Based on treatment type, the Europe lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The compression devices and bandaging segment dominated the market in 2020 and debulking procedures segment is expected to be the fastest growing during the forecast period. Further physiological procedures segment is bifurcated into lymphovenous anastomosis (LVA) and vascularised lymph node transfer (VLNT).Based on end-user, the Europe lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others. The hospitals segment dominated the market in 2020 and clinics is expected to be the fastest growing during the forecast period. Based on country, Europe lymphedema treatment market is classified into UK, Germany, France, Italy, Spain, and Rest of Europe.
Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. For instance, according to the Worldsometer, as of January 2022, 101,188,010 total cases, and 1,565,203 deaths have been registered due to COVID–19 in Europe. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than during the first wave earlier last year. Lockdowns are being reintroduced in the UK, Spain, Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, many countries' government is working towards boosting up their treatments and regenerative medicines technologies for development of various diseases including COVID-19. Additionally, in the UK, the practice of cancer and neurological diseases has changed. Increasing COVID-19 has affected the diagnosis and treatment of diseases, due to the diversification of the medical workforce and decision to focus on treating the critically ill. Due to the current pandemic, many research organizations, are focusing more on COVID 19 studies and are working hard to better understand the virus. The lymphedema treatment market witnessed a shortfall at the beginning of the COVID-19 crisis due to disruption in the supply chain and slumped demand of medical devices (used for the treatment of lymphedema) due to the lockdown announced by most European countries that caused disruptions in manufacturing and operations in the sector. Additionally, appointments and operations have been delayed in many clinics around the world due to increasing cases, as approximately 40% of the diagnosed COVID-19 cases required hospitalisation; and some critical cases were admitted to intensive care units (ICU). According to an article in Vascular News, in the first week of the pandemic outbreak, there was an 80 percent reduction in beds and an 84 percent reduction in operating rooms for elective procedures, with 43 percent of hospitals in Italy not doing any elective surgery. With the number of rising cases, there was a significant decrease in procedures due to a lack of healthcare resources. It also impacted the new product launches, impacting sales and growth of the market in the region. However, with the implementation of proper guidelines and protocols by the European Commission to reduce SARS-CoV-2 exposure and ease in restrictions on movement, the market is expected to grow in the forecast period.
3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are among the leading companies in the Europe lymphedema treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Mego Afek ltd. has announced preliminary data for Lympha Press PCD-51 to be used in chronic venous stasis ulcers.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com